Selegiline Hydrochloride



Indications and Reactions:

Role Indications Reactions
Primary
Parkinson's Disease 40.0%
Cataplexy 20.0%
Narcolepsy 20.0%
Pain 20.0%
Drug Interaction 33.3%
Liver Function Test Abnormal 33.3%
Suicidal Ideation 33.3%
Secondary
Parkinson's Disease 70.7%
Drug Use For Unknown Indication 3.7%
Influenza 3.7%
Arthralgia 2.4%
Depression 2.4%
Glaucoma 1.8%
Hypertension 1.8%
Insomnia 1.8%
Prostate Cancer 1.8%
Drug Effect Decreased 1.2%
Gastric Ulcer 1.2%
Muscle Tightness 1.2%
Neck Pain 1.2%
Oesophagitis Haemorrhagic 1.2%
Angina Pectoris 0.6%
Benign Prostatic Hyperplasia 0.6%
Cerebral Infarction 0.6%
Dysthymic Disorder 0.6%
Hypertonic Bladder 0.6%
Nausea 0.6%
Pre-existing Condition Improved 12.9%
Hallucination 6.5%
On And Off Phenomenon 6.5%
Pneumonitis 6.5%
Pyrexia 6.5%
Road Traffic Accident 6.5%
Somnolence 6.5%
Sympathicotonia 6.5%
Syncope 6.5%
Delirium 3.2%
Drug Interaction 3.2%
Drug Withdrawal Syndrome 3.2%
Hallucination, Visual 3.2%
Hypokinesia 3.2%
Interstitial Lung Disease 3.2%
Nausea 3.2%
Neuroleptic Malignant Syndrome 3.2%
Parkinson's Disease 3.2%
Pathological Gambling 3.2%
Pneumonia 3.2%
Concomitant
Parkinson's Disease 53.3%
Hypertension 7.9%
Drug Effect Decreased 3.9%
Insomnia 3.9%
Nocardiosis 3.7%
Parkinsonism 3.2%
Product Used For Unknown Indication 3.0%
Osteoporosis 2.8%
Back Pain 2.4%
Constipation 2.2%
Drug Use For Unknown Indication 2.2%
Benign Prostatic Hyperplasia 2.0%
Type 2 Diabetes Mellitus 1.8%
Rheumatoid Arthritis 1.4%
Gastrooesophageal Reflux Disease 1.2%
Prostate Cancer Stage Iii 1.2%
Reflux Oesophagitis 1.2%
Cerebral Infarction 1.0%
Gastritis Prophylaxis 1.0%
Hyperlipidaemia 1.0%
Hallucination 10.7%
Parkinson's Disease 9.3%
Pyrexia 6.7%
Respiratory Failure 6.7%
Restlessness 6.7%
Somnolence 5.3%
Sudden Onset Of Sleep 5.3%
Altered State Of Consciousness 4.0%
Cardiac Failure 4.0%
Death 4.0%
Duodenal Ulcer 4.0%
Malaise 4.0%
Orthostatic Hypotension 4.0%
Osteomyelitis 4.0%
Parkinsonism 4.0%
Speech Disorder 4.0%
Stress 4.0%
Wound Complication 4.0%
Cerebral Infarction 2.7%
Delusion 2.7%